AUTHOR AND EDITOR INFORMATION

Section 1 of 10  

• Authors and Editors
• Introduction
• Clinical
• Differentials
• Workup
• Treatment
• Medication
• Follow-up
• Miscellaneous
• References

INTRODUCTION

Section 2 of 10  

• Authors and Editors
• Introduction
• Clinical
• Differentials
• Workup
• Treatment
• Medication
• Follow-up
• Miscellaneous
• References

Background

Fabry disease is an X-linked lysosomal disorder that leads to excessive deposition of neutral glycosphingolipids in the vascular endothelium of several organs in the body. Progressive endothelial accumulation of glycosphingolipids accounts for the associated clinical abnormalities of skin, eye, kidney, heart, brain, and peripheral nervous system.

When young patients present with signs and symptoms of a stroke, along with a history of skin lesions, renal insufficiency or failure, and heart attacks, Fabry disease is a consideration. Recent research suggests that Fabry mutations may be more frequent than previously thought in cryptogenic stroke patients, but these patients invariably had other signs of Fabry disease including proteinuria and acroparesthesias. The diagnosis of Fabry disease has considerable implications regarding treatment, management, and counseling. Specifically, physicians may be alert to the involvement of other organs besides those of the CNS and thus make early intervention possible. With early identification, counseling and prenatal diagnosis may be offered to family members.

Pathophysiology

Deficiency of alpha-galactosidase A activity leads to lysosomal accumulation of glycosphingolipids, predominantly the cerebroside trihexosides. Diffuse abnormal accumulation of glycosphingolipids occurs in all tissues.

Accumulation of glycosphingolipids produces swelling and proliferation of endothelial cells. Abnormal reactivity of endothelial cells with changes in blood flow in the brain and in peripheral vessels has been documented on magnetic resonance (MR) imaging, positron emission tomography (PET), transcranial Doppler imaging (TCD), and plethysmography.

Disturbances in intraluminal pressure and angioarchitecture are thought to lead to dilatation, angiectasia, and dolichoectasia. The vertebrobasilar arteries appear particularly susceptible to dilatational arteriopathy. Small penetrating arteries frequently become narrowed and occluded. Cerebral infarcts result from direct vascular occlusion or stretching and from distention of branches of the dolichoectatic parent vessels.

The precise cause of increased incidence of stroke is not established. Findings that could contribute to this increased risk include abnormal nitric oxide and non-nitric oxide dependent endothelial dilation and abnormal endothelial nitric oxide synthase (eNOS) activity leading to aberrant vascular functioning. Paradoxical hyperperfusion is seen in strokelike lesions whose significance is not known.

Nonischemic compressive complications of dolichoectatic intracranial arteries include hydrocephalus, optic atrophy, trigeminal neuralgia, and cranial nerve palsies.

Frequency

International

The prevalence of Fabry disease has been previously estimated to be 1 per 40,000. Most of the patients are Caucasian, but it is also found in African Americans and those of Hispanic or Asian descent.

• A recent prospective multicenter study of cryptogenic strokes from Germany suggests that the prevalence could be as high as 1.2%. This would mean that the prevalence rate is higher than mutations of factor V Leiden.

Mortality/Morbidity

Because Fabry disease affects several organ systems, morbidity and mortality are related to the combined effects of renal failure, heart failure, and stroke.

• The rate of stroke is reportedly 10-24%. However, this rate may be an overestimation because the data are from tertiary referral centers. About 70% of cerebral infarcts are in the vertebrobasilar circulation; most of the remainder involves the perforating arteries in the anterior circulation. Intracranial hemorrhage is rare.
• Recurrence of cerebrovascular events is common, and lesion load (measured radiologically) increases with advancing age.
• Death, as a result of renal failure, heart failure, or strokes, commonly occurs by the fifth decade.

Sex

• Fabry disease follows X-linked genetics, manifesting predominantly in men.
• Female heterozygotes can also present with clinical and laboratory features of Fabry disease.

Age

• Different investigators have reported that the mean age of hemizygotic men at the onset of symptomatic stroke is 29-38 years.
• The mean age of female heterozygotes at the onset of symptomatic strokes is 40-43 years.

CLINICAL

Section 3 of 10  

• Authors and Editors
• Introduction
• Clinical
• Differentials
• Workup
• Treatment
• Medication
• Follow-up
• Miscellaneous
• References

History

Patients with Fabry disease seek care from a variety of specialists, usually because of the involvement of a number of organ systems. Hypertension occurs with increased frequency in patients with Fabry disease because of progressive renal impairment. Other traditional risk factors for stroke, such as diabetes, hypercholesterolemia, and smoking, may or may not be present in these patients. Fabry disease must be high on the list of differential diagnoses when a young man presents with signs and symptoms of stroke, along with other characteristic lesions, as described below.

• Vague complaints of pain in hands and feet may be a presenting feature. These symptoms are called acroparesthesias, as they reflect the peripheral neuropathy that is a frequent manifestation of the disease.
• • This pain may be both episodic and chronic.
  • Acute episodes may be triggered by exposure to extremes of temperature, stress, emotion, and/or fatigue.
• Punctate, nonblanching, dark red to blue-black cutaneous vascular lesions (angiokeratomas) may be discovered on different parts of the body.
• Lens opacities and retinal and conjunctival vascular malformations may be found in the eyes.
• Left ventricular hypertrophy, conduction defects, valvular deficiencies, and myocardial infarctions are cardiac manifestations of disease in some patients.
• Proteinuria and progressive renal failure are a result of glycosphingolipid accumulation in the renal glomeruli and tubules.
• Hemiparesis, vertigo, diplopia, dysarthria, hemianopia, sensory loss, and other typical stroke symptoms characterize CNS involvement.
• The patient's family history, mostly in men and rarely in women may be positive for Fabry disease because of its X-linked genetic inheritance pattern.

Physical

The diffuse involvement of different organ systems leads to a number of abnormalities that can be discovered on physical examination.

• Abundant punctate, nonblanching clusters of ectatic blood vessels may be found just below the skin on different parts of the body, especially in a bathing-trunk distribution. These are the angiokeratomas, also referred to as angiokeratoma corporis diffusum universale.
• Lenticular opacities and vascular lesions of the conjunctiva and retina may be present.
• Cardiomegaly and rhythm abnormalities may be evident on chest palpation and auscultation.
• A detailed neurologic examination may reveal peripheral neuropathy, or nystagmus, internuclear ophthalmoplegia, dysarthria, aphasia, hemiparesis, and sensory loss caused by stroke lesions, especially in the posterior circulation.

Causes

Fabry disease is an X-linked genetic disease.

DIFFERENTIALS

Section 4 of 10  

• Authors and Editors
• Introduction
• Clinical
• Differentials
• Workup
• Treatment
• Medication
• Follow-up
• Miscellaneous
• References

WORKUP

Section 5 of 10  

• Authors and Editors
• Introduction
• Clinical
• Differentials
• Workup
• Treatment
• Medication
• Follow-up
• Miscellaneous
• References

Lab Studies

• Microscopic examination of urine may show lipid-laden epithelial cells.
• Electrolyte imbalances reflecting renal failure may be seen.
• When an acute stroke is suspected on clinical grounds, customary laboratory tests such as determinations of the CBC count, electrolytes, prothrombin time, and activated partial thromboplastin time should be ordered. A search for the etiology of the symptoms should commence.
• Level of globotriaosylceramide (Gb₃ or GL-3) a glycosphingolipid may be elevated.
• Enzymatic analysis performed by using plasma or leukocytes may show a deficiency of alpha-galactosidase A.
• Levels of Gb₃ and alpha-galactosidase A may be normal in female heterozygote Fabry patients. Therefore, genetic and/or molecular diagnosis is necessary to confirm Fabry disease if suspected based on clinical features of proteinuria and acroparesthesias that were invariably present in both men and women with Fabry mutation and cryptogenic stroke. Men with Fabry mutation tend to have more clinical features when presenting with stroke.

Imaging Studies

• Cardiomegaly may be readily evident on a chest radiograph.
• Echocardiography may be indicated to investigate a possible source of emboli. Echocardiograms may reveal valvular abnormalities, ventricular hypertrophy, and flow abnormalities.
• Brain MRIs or CT scans should be obtained to visualize the site and extent of infarction.
• MR angiography (MRA), CT angiography (CTA), or four-vessel cerebral angiography should be performed to identify large-vessel dilated arteriopathy, stenosis, or occlusion.
• In patients with acute ischemic stroke, diffusion-weighted MRI may be used to identify early lesions, and perfusion-weighted MRI can be performed to identify perfusion defects.
• MR spectroscopy, arterial spin tagged MR imaging, and positron emission tomography (PET) have been performed on an experimental basis to understand the pathophysiology of this disease.

Other Tests

• ECG may show conduction abnormalities and evidence of previous myocardial infarctions.
• Nerve conduction studies may show decreased conduction velocities and prolonged distal latencies.
• Prenatal diagnosis can be made by using samples of chorionic villi and amniotic cells.

Procedures

• Skin biopsy with cells showing increased lipid content is suggestive of Fabry disease.

Histologic Findings

Lipid-laden cells have been described in endothelial cells, epithelial cells, muscle fibers, and ganglion cells.

TREATMENT

Section 6 of 10  

• Authors and Editors
• Introduction
• Clinical
• Differentials
• Workup
• Treatment
• Medication
• Follow-up
• Miscellaneous
• References

Medical Care

• Antiplatelet agents have been used for secondary stroke prevention in Fabry disease, but their effectiveness in this setting has not been proved.
• Anticoagulants may be necessary if embolic events that stem from cardiac causes are a concern.
• Painful neuropathies may be treated with a variety of medications. Carbamazepine and phenytoin have been used anecdotally in Fabry disease.
• Two enzymes, agalsidase-alpha (Replagal) and agalsidase-beta (Fabrazyme), reportedly help in normalizing renal function, cardiac function, and cerebrovascular flow.
• • Whether therapy with these enzymes changes the natural history of strokes attributable to Fabry disease is unclear.
  • Medical regulatory requirements are different in various parts of the world, and the appropriate authorities should be consulted regarding the approval status of these enzymes.
  • Research to replenish deficient enzymes by means of gene transfer via adenovirus is in its early stages.

Surgical Care

• Renal failure is a clear indication for renal transplantation. However, renal transplantation may not alter the course of disease progression in other organ systems.
• Fetal liver transplantation has been tried in a small number of patients.
• • In the limited group of patients tested, no changes in serum or leukocyte alpha-galactosidase A levels were reported.
  • Clinical use of this experimental procedure should be undertaken with caution, since published literature on this topic is sparse.

Consultations

• Consultation with a neurologist is recommended if Fabry disease is suspected as a cause of stroke or if the usual causes of stroke are not present. A neurologist also better handles painful neuropathies not amenable to treatment in the primary care setting.
• If an embolic event is thought to have caused a stroke, a cardiologist's expertise can be sought for both diagnostic and therapeutic options.
• A nephrologist should be consulted if a patient has renal failure.
• Sessions with a physical therapist and an occupational therapist can be helpful in rehabilitative efforts.

MEDICATION

Section 7 of 10  

• Authors and Editors
• Introduction
• Clinical
• Differentials
• Workup
• Treatment
• Medication
• Follow-up
• Miscellaneous
• References

Antiplatelet agents are used for secondary stroke prevention. Anticoagulation with warfarin is prescribed when a cardioembolic stroke is suspected. Painful neuropathies can be treated with a variety of medications, including carbamazepine or phenytoin.

Two enzymes, agalsidase-alpha (Replagal) and agalsidase-beta (Fabrazyme), reportedly help in normalizing renal function, cardiac function, and cerebrovascular flow. Whether therapy with these enzymes changes the natural history of strokes attributable to Fabry disease is unclear.

Drug Category: Antiplatelet agents

These agents inhibit the cyclooxygenase system, decreasing the level of thromboxane A₂, which is a potent platelet activator.

Drug Category: Anticoagulants

These agents are used in the treatment of clinically evident intravascular thrombosis.

Drug Category: Enzyme replacement agents

These agents are the recombinant form of the enzyme alpha-galactosidase and beta-galactosidase-A.

FOLLOW-UP

Section 8 of 10  

• Authors and Editors
• Introduction
• Clinical
• Differentials
• Workup
• Treatment
• Medication
• Follow-up
• Miscellaneous
• References

In/Out Patient Meds:

• Antiplatelet agents: Aspirin, ticlopidine, clopidogrel, and aspirin-dipyridamole in doses mentioned in the Medication section are used routinely to prevent recurrent ischemic strokes of thrombotic type.
• Anticoagulant: Warfarin is often used to prevent cardioembolic strokes.

Transfer:

• Fabry disease is uncommon, and its diagnosis and treatment can be challenging.
• Treatment strategies involve combined efforts from multiple specialties. The diagnosis and care of these patients usually is best handled at tertiary care centers.
• Acute strokes may be managed adequately in community hospitals in the initial phases.
• Aggressive efforts to diagnose the etiology of stroke are necessary to plan secondary prevention strategies. In this context, unusual presentations with multiple organ involvement or lack of traditional vascular risk factors should suggest consideration of Fabry disease. Traditional secondary stroke prevention strategies are still necessary.
• Further care can be accomplished by means of consultation with tertiary care centers.

Prognosis:

• Fabry disease affects multiple organ systems in the body. Death, a result of renal failure, heart involvement, or stroke, usually occurs by the fifth decade.
• After a first stroke, recurrent stroke is frequent, with a median interval to first recurrence of 6.4 years in hemizygotes.

Patient Education:

• For excellent patient education resources, visit eMedicine's Stroke Center. Also, see eMedicine's patient education article Stroke.

MISCELLANEOUS

Section 9 of 10  

• Authors and Editors
• Introduction
• Clinical
• Differentials
• Workup
• Treatment
• Medication
• Follow-up
• Miscellaneous
• References

Medical/Legal Pitfalls

• Signs and symptoms of Fabry disease may be nonspecific. If manifestations in different organs are considered in isolation, the unifying diagnosis may be missed.
• If the family history suggests a diagnosis of Fabry disease, genetic testing and counseling should be offered to all family members, regardless of their sex.

REFERENCES

Section 10 of 10

• Authors and Editors
• Introduction
• Clinical
• Differentials
• Workup
• Treatment
• Medication
• Follow-up
• Miscellaneous
• References

• Altarescu G, Moore DF, Pursley R, et al. Enhanced endothelium-dependent vasodilation in Fabry disease. Stroke. Jul 2001;32(7):1559-62. [Medline].
• Altarescu G, Moore DF, Schiffmann R. Effect of genetic modifiers on cerebral lesions in Fabry disease. Neurology. Jun 28 2005;64(12):2148-50. [Medline].
• Case records of the Massachusetts General Hospital. Weekly clinicopathological exercises. Case 39-1998. A 13-year-old girl with a relapsing-remitting neurologic disorder [clinical conference]. N Engl J Med. Dec 24 1998;339(26):1914-23. [Medline].
• Crutchfield KE, Patronas NJ, Dambrosia JM, et al. Quantitative analysis of cerebral vasculopathy in patients with Fabry disease. Neurology. Jun 1998;50(6):1746-9. [Medline].
• Desnick RJ, Yiannis AI, Eng CM. Alpha-galactosidase A deficiency: Fabry's disease. The Metabolic and Molecular Bases of Inherited Disease. 1995;2741-2784.
• Desnick RJ, Brady R, Barranger J, et al. Fabry disease, an under-recognized multisystemic disorder: expert recommendations for diagnosis, management, and enzyme replacement therapy. Ann Intern Med. Feb 18 2003;138(4):338-46. [Medline].
• Eng CM, Guffon N, Wilcox WR, et al. Safety and efficacy of recombinant human alpha-galactosidase A--replacement therapy in Fabry''s disease. N Engl J Med. Jul 5 2001;345(1):9-16. [Medline].
• Frustaci A, Chimenti C, Ricci R, et al. Improvement in cardiac function in the cardiac variant of Fabry''s disease with galactose-infusion therapy. N Engl J Med. Jul 5 2001;345(1):25-32. [Medline].
• Grewal RP. Stroke in Fabry''s disease. J Neurol. Jan 1994;241(3):153-6. [Medline].
• Gustafsson D, Elg M. The pharmacodynamics and pharmacokinetics of the oral direct thrombininhibitor ximelagatran and its active metabolite melagatran: amini-review. Thromb Res. Jul 15 2003;109 Suppl 1:S9-15. [Medline].
• Hilz MJ, Kolodny EH, Brys M, et al. Reduced cerebral blood flow velocity and impaired cerebral autoregulation in patients with Fabry disease. J Neurol. May 2004;251(5):564-70. [Medline].
• Mehta A, Ricci R, Widmer U, et al. Fabry disease defined: baseline clinical manifestations of 366 patients in the Fabry Outcome Survey. Eur J Clin Invest. Mar 2004;34(3):236-42. [Medline].
• Menkes DL. Images in neurology. The cutaneous stigmata of Fabry disease: an X- linked phakomatosis associated with central and peripheral nervous system dysfunction. Arch Neurol. Apr 1999;56(4):487. [Medline].
• Menkes DL, O''Neil TJ, Saenz KK. Fabry''s disease presenting as syncope, angiokeratomas, and spoke-like cataracts in a young man: discussion of the differential diagnosis. Mil Med. Nov 1997;162(11):773-6. [Medline].
• Mitsias P, Levine SR. Cerebrovascular complications of Fabry''s disease. Ann Neurol. Jul 1996;40(1):8-17. [Medline].
• Moore DF, Altarescu G, Ling GS, et al. Elevated cerebral blood flow velocities in Fabry disease with reversal after enzyme replacement. Stroke. Feb 2002;33(2):525-31. [Medline].
• Moore DF, Altarescu G, Barker WC, et al. White matter lesions in Fabry disease occur in 'prior' selectively hypometabolic and hyperperfused brain regions. Brain Res Bull. Dec 30 2003;62(3):231-40. [Medline].
• Moore DF, Ye F, Brennan ML, et al. Ascorbate decreases Fabry cerebral hyperperfusion suggesting a reactive oxygen species abnormality: an arterial spin tagging study. J Magn Reson Imaging. Oct 2004;20(4):674-83. [Medline].
• Moore DF, Scott LT, Gladwin MT, et al. Regional cerebral hyperperfusion and nitric oxide pathway dysregulation in Fabry disease: reversal by enzyme replacement therapy. Circulation. Sep 25 2001;104(13):1506-12. [Medline].
• Park J, Murray GJ, Limaye A, et al. Long-term correction of globotriaosylceramide storage in Fabry mice by recombinant adeno-associated virus-mediated gene transfer. Proc Natl Acad Sci U S A. Mar 18 2003;100(6):3450-4. [Medline].
• Rolfs A, Bottcher T, Zschiesche M, et al. Prevalence of Fabry disease in patients with cryptogenic stroke: a prospective study. Lancet. Nov 19 2005;366(9499):1794-6. [Medline].
• Schiffmann R, Murray GJ, Treco D, et al. Infusion of alpha-galactosidase A reduces tissue globotriaosylceramide storage in patients with Fabry disease. Proc Natl Acad Sci U S A. Jan 4 2000;97(1):365-70. [Medline].
• Schiffmann R, Ries M. Fabry's disease--an important risk factor for stroke. Lancet. Nov 19 2005;366(9499):1754-6. [Medline].
• Swaiman KF. Lysosomal diseases. In: Ashwal S, Swaiman KF, eds. Pediatric neurology: Principles and Practice. St Louis: Mosby. 1999.
• Tedeschi G, Bonavita S, Banerjee TK, et al. Diffuse central neuronal involvement in Fabry disease: a proton MRS imaging study. Neurology. May 12 1999;52(8):1663-7. [Medline].
• Utsumi K, Yamamoto N, Kase R, et al. High incidence of thrombosis in Fabry''s disease. Intern Med. May 1997;36(5):327-9. [Medline].
• Weidemann F, Breunig F, Beer M, et al. Improvement of cardiac function during enzyme replacement therapy in patients with Fabry disease: a prospective strain rate imaging study. Circulation. Sep 16 2003;108(11):1299-301. [Medline].
• Wilcox WR, Banikazemi M, Guffon N, et al. Long-term safety and efficacy of enzyme replacement therapy for Fabry disease. Am J Hum Genet. Jul 2004;75(1):65-74. [Medline].
• Zweifler RM. Management of acute stroke. South Med J. Apr 2003;96(4):380-5. [Medline].

Article Last Updated: Jun 14, 2006